Special Report: One Year On At The Medicines Patent Pool: Interview With Greg Perry
Greg Perry has been executive director of the Medicines Patent Pool (MPP) for over a year now, since January 2013. Under his guidance, MPP shares that it has launched a “series of new licensing agreements and negotiations with key patent holders and generic medicines companies.” Intellectual Property Watch sat down with Perry recently to discuss why the MPP is so important as an alternative business model, the context of the MPP, changes in the global approach to the issue of access, and how the MPP fits within the Geneva context.
